Equity Mates Investing Podcast

The drug beating Ozempic, Pimp my Portfolio with Luke Laretive & Australia's most popular small caps

20 snips
Feb 25, 2026
Guest
Luke Laretive
Luke Laretive, an investment pro from Seneca who reviews portfolios and asset allocation, joins to dissect market trends. Conversation jumps from the GLP-1 weight-loss drug surge and the Novo vs Eli Lilly battle. Luke also breaks down portfolio gearing, satellite stock sizing, private equity access for retail, and which Australian small caps are catching managers’ eyes.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

GLP-1 Drugs Have Rapid Mainstream Adoption

  • GLP-1 weight loss drugs adoption is massive with 18% of US adults having tried them and ~12% currently using them.
  • Usage skews older and wealthier: 22% of 50–64-year-olds currently take GLP-1s, driving large industry revenue forecasts ($80B to $130–250B).
INSIGHT

Clinical Results Shift Market Leadership Quickly

  • Head-to-head trial results show Eli Lilly's drug outperformed Novo Nordisk's next-generation candidate, causing big market moves.
  • Novo's Kagri-semi delivered ~23% vs Eli Lilly ~25.5% weight loss and Novo's share price fell double digits as investors priced market-share loss risk.
ADVICE

Only Gear After A Market Pullback

  • Only add gearing when markets have retraced or when assets look cheap, not at market highs.
  • Define clear core/satellite allocation first and then decide total portfolio gearing to avoid overexposure and forced cash calls.
Get the Snipd Podcast app to discover more snips from this episode
Get the app